Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pulmonary Embolism in Exacerbations of Chronic Obstructive Pulmonary Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01318174
Recruitment Status : Completed
First Posted : March 18, 2011
Last Update Posted : July 8, 2014
Sponsor:
Information provided by (Responsible Party):
Aleksander Talgøy Holten, Sykehuset Innlandet HF

Tracking Information
First Submitted Date March 17, 2011
First Posted Date March 18, 2011
Last Update Posted Date July 8, 2014
Study Start Date April 2011
Actual Primary Completion Date April 2012   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: July 7, 2014)
Prevalence of pulmonary embolism in exacerbations of COPD [ Time Frame: one year ]
Original Primary Outcome Measures Not Provided
Change History
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Pulmonary Embolism in Exacerbations of Chronic Obstructive Pulmonary Disease
Official Title Prevalence of Pulmonary Embolism in Exacerbations of Chronic Obstructive Pulmonary Disease
Brief Summary The purpose of this study is to determine the prevalence of pulmonary embolism in our population of Chronic Obstructive Pulmonary Disease (COPD) patients admitted to hospital with dyspnea. The patients will undergo investigation for pulmonary embolism, according to current guidelines.
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population Patients with known or suspected COPD admitted with an exacerbation of unknown aetiology
Condition
  • Pulmonary Embolism
  • Chronic Obstructive Pulmonary Disease
Intervention Not Provided
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: July 7, 2014)
38
Original Estimated Enrollment
 (submitted: March 17, 2011)
100
Actual Study Completion Date April 2013
Actual Primary Completion Date April 2012   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • known or suspected COPD
  • COPD-exacerbation

Exclusion Criteria:

  • other causes of dyspnea
  • unable to perform CT pulmonary angio (contrast allergy, pregnancy)
  • already included in the study (each patient included only once)
  • use of anticoagulants
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Norway
Removed Location Countries  
 
Administrative Information
NCT Number NCT01318174
Other Study ID Numbers LE-KE
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Aleksander Talgøy Holten, Sykehuset Innlandet HF
Study Sponsor Sykehuset Innlandet HF
Collaborators Not Provided
Investigators
Principal Investigator: Aleksander T Holten, PhD Sykehuset Innlandet HF
PRS Account Sykehuset Innlandet HF
Verification Date July 2014